Eisai Launches New Dry Syrup Formulation of Aricept in Japan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eisai Launches New Dry Syrup Formulation of Aricept in Japan
Eisai has launched a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan.


Eisai has launched a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan. Aricept dry syrup 1% is a suspension formulation that allows the dosage to be adjusted within the range of approved dosage amounts at the time of administration according to individual patient needs. The dry syrup can be taken with water in the same way as the existing fine granules formulation but is only half as bulky, making it easier for patients who have difficulty swallowing the existing formulation.

Aricept is indicated for the treatment of mild to severe Alzheimer's disease. A wide range of formulations are available, such as tablets, orally disintegrating tablets, fine granules and an oral jelly formulation to meet the various needs of patients and caregivers. Eisai's new formulation of Aricept is the first dry syrup to have been approved for the treatment of Alzheimer's disease according to the company’s press release. Eisai received manufacturing and marketing authorization for the new formulation in February 2013. The dry syrup formulation provides an alternative for patients with dysphagia or other difficulties in administering the drug.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here